-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, DQeriFzoJRijpVrLEp0hg0XraEVmJEvtnSeTTajWMi7ERM1uEZZntWU1CsYeqNFe GfW29xFqOs5i+YEcT5cmsA== 0001011438-00-000117.txt : 20000214 0001011438-00-000117.hdr.sgml : 20000214 ACCESSION NUMBER: 0001011438-00-000117 CONFORMED SUBMISSION TYPE: SC 13G PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20000211 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: MEDITECH PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000717588 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 953819300 STATE OF INCORPORATION: NV FISCAL YEAR END: 0531 FILING VALUES: FORM TYPE: SC 13G SEC ACT: SEC FILE NUMBER: 005-36623 FILM NUMBER: 536012 BUSINESS ADDRESS: STREET 1: 10105 E VIA LINDA STREET 2: 103 382 CITY: SCOTTSDALE STATE: AZ ZIP: 85258 BUSINESS PHONE: 6026142874 MAIL ADDRESS: STREET 1: 10105 E VIA LINDA STREET 2: 103 382 CITY: SCOTTSDALE STATE: AZ ZIP: 85258 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: IMMUNE NETWORK RESEARCH LTD CENTRAL INDEX KEY: 0001097907 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731] IRS NUMBER: 891078933 STATE OF INCORPORATION: A1 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G BUSINESS ADDRESS: STREET 1: 3650 WESBROOK MALL STREET 2: VANCOUVER BRITISH COLUMBIA CITY: CANADA V6S 2L2 STATE: A1 ZIP: 00000 BUSINESS PHONE: 6042225541 MAIL ADDRESS: STREET 1: 3650 WESBROOK MALL STREET 2: VANCOUVER BC CANADA V6S 2L2 CITY: VANCOUVER BC STATE: A1 SC 13G 1 SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (RULE 13D-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13D-1(B)(C), AND (D) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13D-2(B) (AMENDMENT NO. ___________)1 Meditech Pharmaceuticals, Inc. - -------------------------------------------------------------------------------- (Name of Issuer) Common Stock - -------------------------------------------------------------------------------- (Title of Class of Securities) 58491310 - -------------------------------------------------------------------------------- (CUSIP Number) February 3, 2000 - -------------------------------------------------------------------------------- (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: |_| Rule 13d-1(b) |X| Rule 13d-1(c) |_| Rule 13d-1(d) -------- 1 The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior coverage page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). SEC 1745 (2-95) CUSIP No. 58491310 13G Page 1 of 4 Pages - ------------------ ----------------- ________________________________________________________________________________ 1. NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY) IMMUNE NETWORK RESEARCH LTD. ________________________________________________________________________________ 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [_] (b) [_] ________________________________________________________________________________ 3. SEC USE ONLY ________________________________________________________________________________ 4. CITIZENSHIP OR PLACE OF ORGANIZATION BRITISH COLUMBIA, CANADA ________________________________________________________________________________ NUMBER OF 5. SOLE VOTING POWER 10,000,000 (includes 10,000,000 shares issuable under SHARES an option exercisable within 60 days of February 3, 2000). BENEFICIALLY _________________________________________________________________ 6. SHARED VOTING POWER OWNED BY N/A EACH _________________________________________________________________ 7. SOLE DISPOSITIVE POWER REPORTING 10,000,000 (includes 10,000,000 shares issuable under an option exercisable within 60 days of PERSON February 3, 2000). _________________________________________________________________ WITH 8. SHARED DISPOSITIVE POWER N/A ________________________________________________________________________________ 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 10,000,000 ________________________________________________________________________________ 10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* [_] ________________________________________________________________________________ 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 7.2% ________________________________________________________________________________ 12. TYPE OF REPORTING PERSON* CO ________________________________________________________________________________ *SEE INSTRUCTIONS BEFORE FILLING OUT! ITEM 1(A).NAME OF ISSUER: Meditech Pharmaceuticals, Inc. ITEM 1(B).ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES: 10105 E. Via Linda, #103 Scottsdale, Arizona 85258 ITEM 2(A).NAME OF PERSON FILING: Immune Network Research Ltd. ITEM 2(B).ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE: 3650 Wesbrook Mall Vancouver, BC V6S 2L2 ITEM 2(C).CITIZENSHIP: British Columbia, Canada ITEM 2(D).TITLE OF CLASS OF SECURITIES: Common Stock ITEM 2(E).CUSIP NUMBER: 58491310 ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO RULE 13D-1(B), 13D-2(B) OR (C), CHECK WHETHER THE PERSON FILING IS A: Not Applicable (a) [ ] Broker or Dealer registered under Section 15 of the Exchange Act; (b) [ ] Bank as defined in Section 3(a)(6) of the Exchange Act; (c) [ ] Insurance Company as defined in Section 3(a)(19) of the Exchange Act; (d) [ ] Investment Company registered under Section 8 of the Investment Company Act; (e) [ ] An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E); (f) [ ] An employee benefit plan or endowment fund in accordance with Rule 13d- 1(b)(1)(ii)(F); (g) [ ] A parent holding company or control person in accordance with Rule 13d - 1(b)(ii)(G); (h) [ ] A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act; (i) [ ] A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act; (j) [ ] Group, in accordance with Rule 13d-1(b)(1)(ii)(J). If this statement is filed pursuant to Rule 13d-1(c), check this box. [x] ITEM 4. OWNERSHIP. Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1. (a) Amount beneficially owned: 10,000,000 shares (includes 10,000,000 shares of an option exercisable within 60 days of February 3, 2000). (b) Percent of class: 7.2% (based on 10,000,000 shares issuable under an option exercisable within 60 days of February 3, 2000 for which beneficial ownership of is reported in this schedule and 139,353,432 shares outstanding as of November 30, 1999 (which includes 129,353,432 shares outstanding as of November 30, 1999 and 10,000,000 shares issuable under the option for which beneficial ownership of is being reported in this schedule)) (c) Number of shares as to which such person has: (i) Sole Power to vote or to direct the vote 10,000,000 (INCLUDES 10,000,000 SHARES ISSUABLE UNDER AN OPTION EXERCISABLE WITHIN 60 DAYS OF FEBRUARY 3, 2000). (ii) Shared Power to vote or to direct the vote 0 SHARES. (iii) Sole Power to dispose or to direct the disposition of 10,000,000 (INCLUDES 10,000,000 SHARES OF AN OPTION EXERCISABLE WITHIN 60 DAYS OF FEBRUARY 3, 2000). (iv) Shared Power to vote or to direct the vote 0 SHARES. ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS. Not Applicable ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON. Not Applicable ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY. Not Applicable ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP. Not Applicable ITEM 9. NOTICE OF DISSOLUTION OF GROUP. Not Applicable ITEM 10. CERTIFICATIONS. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. FEBRUARY 10, 2000 -------------------------------- (Date) /S/ DR. ALLAN BAIN -------------------------------- (Signature) Dr. Allan Bain/President and Chief Executive Officer of Immune Network Research Ltd. -------------------------------- (Name/Title) -----END PRIVACY-ENHANCED MESSAGE-----